More on INKT

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+17.9% Growth)
- Ratings (7.5 Score)

Upcoming Events

- Earnings (8/12/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

MiNK Therapeutics (NQ:INKT)
Delayed: 11.07 --0 (-0%)
Prev. Close $11.07  
Open$11.13 
52 Wk High$ 
52 Wk Low$ 
Day High$11.13 
Day Low$11.07 
P/E N/A  
EPS$ 
Volume1,170 

Friends, Peers and Foes (?): AGEN (more...)

Jun 23, 2026 10:10 AM Form 8-K MiNK Therapeutics, Inc. For: Jun 17
Jun 5, 2026 06:04 PM Form 4 MiNK Therapeutics, Inc. For: Jun 04 Filed by: Ryan Barbara
Jun 3, 2026 04:30 PM MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
Jun 2, 2026 04:06 PM Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: Holcomb John Bradley
Jun 2, 2026 04:06 PM Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: Ryan Barbara
Jun 2, 2026 04:06 PM Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: Corvese Brian
Jun 2, 2026 04:05 PM Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: Behner Peter
Jun 2, 2026 04:05 PM Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: WIINBERG ULF
May 28, 2026 09:05 AM MiNK Therapeutics doses first patient in phase 2 lung injury trial
May 28, 2026 09:04 AM MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
View All Articles

Entities mentioned with INKT

View All Entities